Jpmorgan Chase & CO Neuro Pace Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Neuro Pace Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 64,826 shares of NPCE stock, worth $718,920. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,826
Previous 11,997
440.35%
Holding current value
$718,920
Previous $83,000
773.49%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding NPCE
# of Institutions
61Shares Held
21.4MCall Options Held
23.5KPut Options Held
100-
Kck Ltd. Tortola, D85.27MShares$58.5 Million78.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.41MShares$37.8 Million1.03% of portfolio
-
Morgan Stanley New York, NY2.49MShares$27.6 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$27 Million1.9% of portfolio
-
Kent Lake Pr LLC Anasco, PR1.48MShares$16.4 Million7.02% of portfolio
About NeuroPace Inc
- Ticker NPCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 24,846,900
- Market Cap $276M
- Description
- NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...